Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Fumoleau P, Kerbrat P, Romestaing P, Fargeot P, Brémond A, Namer M, Schraub S, Goudier MJ, Mihura J, Monnier A, Clavère P, Serin D, Seffert P, Pourny C, Facchini T, Jacquin JP, Sztermer JF, Datchary J, Ramos R, Luporsi E. Fumoleau P, et al. Among authors: fargeot p. J Clin Oncol. 2003 Jan 15;21(2):298-305. doi: 10.1200/JCO.2003.04.148. J Clin Oncol. 2003. PMID: 12525522 Clinical Trial.
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J, Roché H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavère P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I. Bonneterre J, et al. Among authors: fargeot p. J Clin Oncol. 2004 Aug 1;22(15):3070-9. doi: 10.1200/JCO.2004.03.098. J Clin Oncol. 2004. PMID: 15284257 Clinical Trial.
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P, Bonneterre J, Roché H, Lortholary A, Campone M, Van Praagh I, Monnier A, Namer M, Schraub S, Barats JC, Guastalla JP, Goudier MJ, Chapelle-Marcillac I. Fargeot P, et al. J Clin Oncol. 2004 Dec 1;22(23):4622-30. doi: 10.1200/JCO.2004.02.145. Epub 2004 Oct 25. J Clin Oncol. 2004. PMID: 15505276 Clinical Trial.
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Bonneterre J, Roché H, Kerbrat P, Brémond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P, Chapelle-Marcillac I. Bonneterre J, et al. Among authors: fargeot p. J Clin Oncol. 2005 Apr 20;23(12):2686-93. doi: 10.1200/JCO.2005.05.059. J Clin Oncol. 2005. PMID: 15837983 Clinical Trial.
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Fumoleau P, Roché H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ, Luporsi E; French Adjuvant Study Group. Fumoleau P, et al. Among authors: fargeot p. Ann Oncol. 2006 Jan;17(1):85-92. doi: 10.1093/annonc/mdj034. Epub 2005 Oct 26. Ann Oncol. 2006. PMID: 16251204 Free article.
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.
Namer M, Fargeot P, Roché H, Campone M, Kerbrat P, Romestaing P, Monnier A, Luporsi E, Montcuquet P, Bonneterre J; French Adjuvant Study Group. Namer M, et al. Among authors: fargeot p. Ann Oncol. 2006 Jan;17(1):65-73. doi: 10.1093/annonc/mdj022. Ann Oncol. 2006. PMID: 16361531 Free article. Clinical Trial.
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Roché H, Kerbrat P, Bonneterre J, Fargeot P, Fumoleau P, Monnier A, Clavère P, Goudier MJ, Chollet P, Guastalla JP, Serin D. Roché H, et al. Among authors: fargeot p. Ann Oncol. 2006 Aug;17(8):1221-7. doi: 10.1093/annonc/mdl107. Epub 2006 May 26. Ann Oncol. 2006. PMID: 16731539 Free article. Clinical Trial.
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P, Roché H, Bonneterre J, Veyret C, Lortholary A, Monnier A, Fumoleau P, Fargeot P, Namer M, Chollet P, Goudier MJ, Audhuy B, Simon H, Montcuquet P, Eymard JC, Walter S, Clavère P, Guastalla JP; French adjuvant Study Group. Kerbrat P, et al. Among authors: fargeot p. Br J Cancer. 2007 Jun 4;96(11):1633-8. doi: 10.1038/sj.bjc.6603773. Epub 2007 May 15. Br J Cancer. 2007. PMID: 17505516 Free PMC article. Clinical Trial.
96 results